These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 20798135)

  • 1. A novel adaptive design strategy increases the efficiency of clinical trials in secondary progressive multiple sclerosis.
    Chataway J; Nicholas R; Todd S; Miller DH; Parsons N; Valdés-Márquez E; Stallard N; Friede T
    Mult Scler; 2011 Jan; 17(1):81-8. PubMed ID: 20798135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Group-sequential methods for adaptive seamless phase II/III clinical trials.
    Stallard N
    J Biopharm Stat; 2011 Jul; 21(4):787-801. PubMed ID: 21516569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological Approaches to the Management of Secondary Progressive Multiple Sclerosis.
    Nandoskar A; Raffel J; Scalfari AS; Friede T; Nicholas RS
    Drugs; 2017 May; 77(8):885-910. PubMed ID: 28429241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Designing Multi-arm Multistage Adaptive Trials for Neuroprotection in Progressive Multiple Sclerosis.
    Li V; Leurent B; Barkhof F; Braisher M; Cafferty F; Ciccarelli O; Eshaghi A; Gray E; Nicholas JM; Parmar M; Peryer G; Robertson J; Stallard N; Wason J; Chataway J
    Neurology; 2022 May; 98(18):754-764. PubMed ID: 35321926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Designing a seamless phase II/III clinical trial using early outcomes for treatment selection: an application in multiple sclerosis.
    Friede T; Parsons N; Stallard N; Todd S; Valdes Marquez E; Chataway J; Nicholas R
    Stat Med; 2011 Jun; 30(13):1528-40. PubMed ID: 21341301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints.
    Jenkins M; Stone A; Jennison C
    Pharm Stat; 2011; 10(4):347-56. PubMed ID: 22328327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adaptive design of confirmatory trials: Advances and challenges.
    Lai TL; Lavori PW; Tsang KW
    Contemp Clin Trials; 2015 Nov; 45(Pt A):93-102. PubMed ID: 26079372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized two-stage Phase II clinical trial designs based on Barnard's exact test.
    Shan G; Ma C; Hutson AD; Wilding GE
    J Biopharm Stat; 2013; 23(5):1081-90. PubMed ID: 23957517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review of Phase III Clinical Trials Outcomes in Patients with Secondary Progressive Multiple Sclerosis.
    McAdams M; Stankiewicz JM; Weiner HL; Chitnis T
    Mult Scler Relat Disord; 2021 Sep; 54():103086. PubMed ID: 34289435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Designs for clinical trials with time-to-event outcomes based on stopping guidelines for lack of benefit.
    Royston P; Barthel FM; Parmar MK; Choodari-Oskooei B; Isham V
    Trials; 2011 Mar; 12():81. PubMed ID: 21418571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adaptive methods: telling "the rest of the story".
    Emerson SS; Fleming TR
    J Biopharm Stat; 2010 Nov; 20(6):1150-65. PubMed ID: 21058111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two-stage response adaptive randomization designs for multi-arm trials with binary outcome.
    Lu X; Shan G
    J Biopharm Stat; 2024 Jul; 34(4):526-538. PubMed ID: 37452825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The inclusion of real world evidence in clinical development planning.
    Martina R; Jenkins D; Bujkiewicz S; Dequen P; Abrams K;
    Trials; 2018 Aug; 19(1):468. PubMed ID: 30157904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design issues in randomized phase II/III trials.
    Korn EL; Freidlin B; Abrams JS; Halabi S
    J Clin Oncol; 2012 Feb; 30(6):667-71. PubMed ID: 22271475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adaptive seamless designs with interim treatment selection: a case study in oncology.
    Carreras M; Gutjahr G; Brannath W
    Stat Med; 2015 Apr; 34(8):1317-33. PubMed ID: 25640198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Data-driven treatment selection for seamless phase II/III trials incorporating early-outcome data.
    Kunz CU; Friede T; Parsons N; Todd S; Stallard N
    Pharm Stat; 2014; 13(4):238-46. PubMed ID: 24789367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 10-year follow-up of the European multicenter trial of interferon β-1b in secondary-progressive multiple sclerosis.
    Kuhle J; Hardmeier M; Disanto G; Gugleta K; Ecsedi M; Lienert C; Amato MP; Baum K; Buttmann M; Bayas A; Brassat D; Brochet B; Confavreux C; Edan G; Färkkilä M; Fredrikson S; Frontoni M; D'Hooghe M; Hutchinson M; De Keyser J; Kieseier BC; Kümpfel T; Rio J; Polman C; Roullet E; Stolz C; Vass K; Wandinger KP; Kappos L;
    Mult Scler; 2016 Apr; 22(4):533-43. PubMed ID: 26362898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statistics in clinical trials.
    Green SJ; Pauler DK
    Curr Oncol Rep; 2004 Jan; 6(1):36-41. PubMed ID: 14664759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrated phase II/III clinical trials in oncology: a case study.
    Wang M; Dignam JJ; Zhang QE; DeGroot JF; Mehta MP; Hunsberger S
    Clin Trials; 2012 Dec; 9(6):741-7. PubMed ID: 23180870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
    Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J
    Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.